J9047
J9047 – Injection, carfilzomib, 1 mg · NDC Crosswalk & Billing Units
HCPCS Level II J-code · Medicare Part B drug billing
J-code
● 6 NDCs crosswalked per 1 MG $60.291/unit ASP+6%
📋 J9047 summary
J9047 is a HCPCS Level II J-code used to bill carfilzomib, 1 mg, billed per 1 MG. The number of billing units to report depends on the dose administered and the NDC/package billed — use the calculator below.
Brand names associated with J9047: Kyprolis
Code J9047
Billing unit 1 MG Payment limit $60.291/unit NDC-Crosswalk 6
Quarter Q3 2026
RxCUI Atlas Trace the drug concept →
⚠ An NDC↔HCPCS crosswalk and a published payment limit do not guarantee payer coverage or payment. Always verify the current payer policy and claim format before billing.
🗂️ Key billing facts
HCPCS codeJ9047
DescriptorInjection, carfilzomib, 1 mg
Billing unit1 MG
Payment limit / unit$60.291
Est. ASP / unit$56.878 est.
Mapped NDCs6
Data periodQ3 2026
Last updated2026-08-20
💊 About Carfilzomib Injection DRUG GUIDE
Kyprolis (carfilzomib) injection is used to treat adults with relapsed or refractory multiple myeloma — a cancer of plasma cells in the bone marrow — whose disease has come back or stopped responding to earlier treatment.
It is approved for patients who have received one or more prior lines of therapy.Kyprolis may be given alone or in combination with other medications, including lenalidomide and dexamethasone, dexamethasone alone, daratumumab and dexamethasone, daratumumab and hyaluronidase-fihj and dexamethasone, or isatuximab and dexamethasone.
The specific combination depends on how many prior treatments a patient has received and what their care team recommends.
Clinical overview from our editorial drug guide for Carfilzomib Injection. For billing reference, see the sections above.
🧾 Billing & reimbursement HCPCS · CMS · EFF. Q3 2026
📅 Payment limits effective Q3 2026 — from the CMS Medicare Part B Payment Limit File (revised quarterly).
Medicare payment limit / unit
$60.291
Est. ASP / unit
$56.878 est.
Est. after 2% sequester
$59.085
HCPCS dosage
1 MG
The CMS payment limit is the Medicare Part B drug allowance (ASP + 6%, statutory). After the 2% federal sequester the effective payment is ≈ ASP + 4.3%; estimated ASP = payment limit ÷ 1.06. Source: CMS Medicare Part B Payment Limit File (quarterly), Q3 2026.
Full HCPCS code details (official CMS record)
Long descriptionInjection, carfilzomib, 1 mg
CoverageC — Carrier/MAC judgment
Pricing indicator51 — Drug — priced under the ASP methodology
Type of service1 — Medical care
BETOS-2O1D
ASC payment groupYY
Action codeN — No maintenance this year
Effective date2014-01-01
Date added2014-01-01
Source: CMS HCPCS Level II code file (imported via admin).
🧮 Dosing & billing-units calculator HCPCS UNITS
One billing unit of J9047 = 1 mg. Enter a regimen to convert dose → billing units and project a full course.
Billing units = dose ÷ HCPCS unit size. Most payers require whole units — round per the payer's policy. “Est. Medicare pay” uses the current payment limit. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (JZ when none is discarded) where allowed. Always verify payer-specific rounding before billing.
🔁 NDCs that bill under J9047 WITH EST. MEDICARE PAY
6 NDCs map to J9047. Bill units = how many HCPCS units one package represents. Est. pay / pkg = payment limit ($60.291/unit) × that package's bill units.
| NDC (11-digit) | Drug | Labeler | Package | Strength | Bill units | Est. pay / pkg | NADAC / unit | Status | Source |
|---|---|---|---|---|---|---|---|---|---|
| 76075-0101-01 | KYPROLIS carfilzomib 60 mg/30mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Onyx | 1 VIAL, SINGLE-USE in 1 CARTON (76075-101-... | 60 mg/30mL | 60 | $3,617.46 | — | ● Active | CMS + PDAC |
| 76075-0101-21 | KYPROLIS carfilzomib 60 mg/30mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Onyx | 1 VIAL, SINGLE-USE in 1 CARTON (76075-101-... | 60 mg/30mL | 60 | $3,617.46 | — | ● Active | CMS + PDAC |
| 76075-0102-01 | KYPROLIS carfilzomib 30 mg/15mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Onyx | 1 VIAL, SINGLE-DOSE in 1 CARTON (76075-102... | 30 mg/15mL | 30 | $1,808.73 | — | ● Active | CMS + PDAC |
| 76075-0102-21 | KYPROLIS carfilzomib 30 mg/15mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Onyx | 1 VIAL, SINGLE-DOSE in 1 CARTON (76075-102... | 30 mg/15mL | 30 | $1,808.73 | — | ● Active | CMS + PDAC |
| 76075-0103-01 | KYPROLIS carfilzomib 10 mg/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Onyx | 1 VIAL, SINGLE-DOSE in 1 CARTON (76075-103... | 10 mg/5mL | 10 | $602.91 | — | ● Active | CMS + PDAC |
| 76075-0103-21 | KYPROLIS carfilzomib 10 mg/5mL INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION | Onyx | 1 VIAL, SINGLE-DOSE in 1 CARTON (76075-103... | 10 mg/5mL | 10 | $602.91 | — | ● Active | CMS + PDAC |
NDC→HCPCS mappings come from the CMS ASP NDC-HCPCS crosswalk; additional DME MAC / DMEPOS mappings come from PDAC and are labeled separately. NADAC from CMS (weekly). “Status” reflects the product's marketing / obsolete flag in the NDC directory. Presence or absence here does not determine Medicare coverage. Linked NDCs open the full product page.
📊 Medicare utilization & spend CMS · PART B · 2026 (Q1)
Period
Total Part B spend
$88.51M
Claims
15,969
Beneficiaries
3,191
Spend / beneficiary
$27,736.50
Spend / claim
$5,542.44
Trend by period
Where J9047 ranks among Part B drugs · 2026 (Q1) · neighbors ±5
Total spending — #38 of 824
#33
IZERVAY J2782
$105.23M
#34
ILUMYA J3245
$103.49M
#35
VYVGART J9332
$103.34M
#36
OCTREOTIDE ACETATE E... J2353
$101.31M
#37
ACTEMRA(J3262) J3262
$99.7M
#38
KYPROLIS J9047
$88.51M
#39
INFLIXIMAB* J1745
$82.56M
#40
HIZENTRA J1559
$79.43M
#41
CIMZIA (2 PACK)* J0717
$79.11M
#42
SIMPONI ARIA J1602
$77.87M
#43
KRYSTEXXA J2507
$76.71M
Total claims — #130 of 824
#125
AMELUZ J7345
16,994
#126
ADACEL TDAP* 90715
16,971
#127
PADCEV J9177
16,557
#128
GELSYN-3 J7328
16,416
#129
GEL-ONE J7326
16,189
#130
KYPROLIS J9047
15,969
#131
BORTEZOMIB(J9041)* J9041
15,380
#132
IRON SUCROSE* J1756
15,220
#133
REBLOZYL J0896
15,092
#134
OMNIPAQUE Q9965
15,067
#135
DEFINITY RT* Q9957
14,931
Top Medicare Part B drugs by the selected metric. Click any drug to open its J-code page. Source: CMS Medicare Quarterly Part B Spending by Drug.
Full breakdown by period (2)
| Period | Total spend | Beneficiaries | Claims | $/beneficiary | $/claim |
|---|---|---|---|---|---|
| 2026 (Q1) | $88.51M | 3,191 | 15,969 | $27,736.50 | $5,542.44 |
| 2025 (Q1-Q4) | $389.26M | 5,693 | 71,261 | $68,375.65 | $5,462.49 |
Provider-administered (Part B) spend, calculated for the whole HCPCS code (CMS does not publish Medicare spend per individual NDC). Self-administered use is covered under Part D instead. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part B Spending by Drug (data.cms.gov), updated quarterly.
📈 Medicare Part B claims detail CMS PSPS · 2024
Calendar-year 2024 Medicare Part B fee-for-service activity for this HCPCS code, summed across all carriers, localities and specialties (CMS Physician/Supplier Procedure Summary). A “service” is one billed line/unit — not one claim — so counts run higher than claim counts.
Allowed charges
$146.51M
Medicare paid
$116.11M
Submitted services
2,887,727
Denial rate
4.7%
Allowed / service
$53.22
Submitted charges
$365.17M
Source: CMS Physician/Supplier Procedure Summary (PSPS), CY2024 — Medicare Part B carrier + DME fee-for-service claims (excludes Medicare Advantage). Figures are for the whole HCPCS code, which may cover uses beyond this drug. ⚠ CMS hides any figure covering fewer than 11 patients (a privacy rule), so totals — especially denials and low-volume codes — run a little low.
🗺️ Where J9047 is utilized CMS · BY PROVIDER · 2024
Medicare Part B services for this code by the rendering provider's state — 162,044 services across 8 states & territories in 2024 (CMS reports include DC and U.S. territories). Switch to per 100k to compare states fairly regardless of population. Hover or tap a state for its top ZIP codes.
Hover or tap a state to see its numbers + top ZIP codes.
Per-capita = services ÷ 2023 state population × 100,000 (so high-population states aren't automatically "hotter"). Counts reflect the provider's location, not the patient's. Providers with fewer than 11 patients are hidden by CMS for privacy, so totals run low and per-100k can be noisy in small states — read this as relative geography, not exact counts. Source: CMS Medicare Physician & Other Practitioners — by Provider and Service, 2024.
📊 What bills under J9047
J-codes are billing codes often used for drugs billed under the medical benefit. This connects the billing code to the NDC package records it covers, by ingredient and labeler.
NDC products by ingredient
NDC products by labeler
🗃️ Data sources & freshness
Every figure on this page is computed from public datasets. Here's what each section draws on and how current it is.
HCPCS code & descriptor
CMS HCPCS Level II code file
Loaded
Payment limit & billing unit
CMS Medicare Part B ASP Pricing File (quarterly)
Q3 2026 · as of 2026-08-20
NDC ↔ HCPCS crosswalk
CMS ASP NDC-HCPCS crosswalk + DMEPDAC (PDAC)
6 NDCs mapped
NADAC acquisition cost
CMS National Average Drug Acquisition Cost (weekly)
Not available for mapped NDCs
Utilization & spend
CMS Part B Spending by Drug · PSPS · Physician & Other Practitioners
Latest data year 2026
Figures are estimates for reference and may lag the source files. Always verify against the current CMS files and your payer's policy before submitting claims.
⚠️ Practical billing caveats
- A crosswalk is not coverage. An NDC mapping or a published payment limit does not guarantee a payer will cover or pay this code. Check the specific plan's policy.
- Units ≠ milligrams. Bill the number of HCPCS units (dose ÷ the code's unit size), not the milligram dose. Use the calculator above.
- Discarded drug. For single-dose vials, drug discarded after administration may be separately billable with modifier JW (and JZ when nothing is discarded) where the payer allows.
- Rounding & partial units. Many payers require whole units; round per the payer's policy, not automatically up.
- The code can cover more than this drug. Some HCPCS codes span multiple products or strengths — confirm the exact code for the product administered.
- Figures lag. ASP limits change quarterly and utilization data are released with a delay. Verify against the current CMS files before billing.
❓ J9047 billing FAQ
What is HCPCS code J9047?
J9047 is a HCPCS Level II J-code used to bill Injection, carfilzomib, 1 mg under Medicare Part B and most medical (not pharmacy) benefits.
What is the billing unit for J9047?
One unit of J9047 represents 1 MG. Report the number of units equal to the dose administered divided by 1 MG.
How many units of J9047 should I bill?
Divide the dose administered by the code's unit size (1 MG) to get the number of billing units, then round per your payer's policy. The calculator on this page converts a dose into billing units and projects a full course.
How much does Medicare pay for J9047?
The Medicare Part B payment limit is $60.291 per unit (Q3 2026), based on ASP + 6%. After the 2% sequester the effective payment is about $59.085 per unit. Payment limits are revised quarterly.
Which NDCs bill under J9047?
6 NDCs currently map to J9047 in the CMS ASP NDC-HCPCS crosswalk. See the NDC crosswalk table above for each product, package, billing units and estimated reimbursement.
Does a crosswalk mean J9047 is covered?
No. An NDC-to-HCPCS crosswalk and a published payment limit do not guarantee coverage or payment. Coverage depends on the payer, the diagnosis and the site of care — always verify the current policy before billing.
For professional billing reference only — verify against the current CMS files before submitting claims.